NasdaqGS - Nasdaq Real Time Price USD

Repligen Corporation (RGEN)

126.50
+3.24
+(2.63%)
At close: May 16 at 4:00:01 PM EDT
126.50
0.00
(0.00%)
After hours: May 16 at 4:33:37 PM EDT
Loading Chart for RGEN
  • Previous Close 123.26
  • Open 124.06
  • Bid 113.67 x 200
  • Ask 126.76 x 700
  • Day's Range 120.11 - 126.56
  • 52 Week Range 102.97 - 182.52
  • Volume 1,228,034
  • Avg. Volume 849,820
  • Market Cap (intraday) 7.107B
  • Beta (5Y Monthly) 1.21
  • PE Ratio (TTM) --
  • EPS (TTM) -0.43
  • Earnings Date Jul 28, 2025 - Aug 1, 2025
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 183.12

Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company also provides chromatography products, including OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes, as well as ELISA test kits. In addition, it offers filtration products, such as XCell ATF Cell Retention Systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has a collaboration agreement with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.

www.repligen.com

1,778

Full Time Employees

December 31

Fiscal Year Ends

Recent News: RGEN

View More

Performance Overview: RGEN

Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

RGEN
12.12%
S&P 500 (^GSPC)
1.30%

1-Year Return

RGEN
26.04%
S&P 500 (^GSPC)
12.48%

3-Year Return

RGEN
15.64%
S&P 500 (^GSPC)
48.66%

5-Year Return

RGEN
9.95%
S&P 500 (^GSPC)
108.07%

Compare To: RGEN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: RGEN

View More

Valuation Measures

Annual
As of 5/16/2025
  • Market Cap

    7.11B

  • Enterprise Value

    7.09B

  • Trailing P/E

    --

  • Forward P/E

    76.34

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    10.90

  • Price/Book (mrq)

    3.58

  • Enterprise Value/Revenue

    10.91

  • Enterprise Value/EBITDA

    81.90

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -3.53%

  • Return on Assets (ttm)

    0.92%

  • Return on Equity (ttm)

    -1.16%

  • Revenue (ttm)

    650.43M

  • Net Income Avi to Common (ttm)

    -22.98M

  • Diluted EPS (ttm)

    -0.43

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    697.23M

  • Total Debt/Equity (mrq)

    34.44%

  • Levered Free Cash Flow (ttm)

    183.66M

Research Analysis: RGEN

View More

Company Insights: RGEN

Research Reports: RGEN

View More

People Also Watch